Search This Blog

Tuesday, July 7, 2026

Lilly results shade Kailera positive Phase 3 topline in obesity and type 2 diabetes

 

Kailera Therapeutics announces positive Phase 3 topline for oral GLP-1 HRS-7535/KAI-7535 in obesity and type 2 diabetes

  • Two Hengrui Pharma Phase 3 trials showed up to 11.1% weight loss and 1.68% HbA1c reduction with HRS-7535/KAI-7535.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)